Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a significant decrease in short interest in February. As of February 13th, there was short interest totaling 62,840 shares, a decrease of 28.5% from the January 29th total of 87,833 shares. Approximately 2.1% of the company’s stock are sold short. Based on an average daily trading volume, of 33,193 shares, the short-interest ratio is currently 1.9 days. Based on an average daily trading volume, of 33,193 shares, the short-interest ratio is currently 1.9 days. Approximately 2.1% of the company’s stock are sold short.

Insider Activity at Exicure

In other news, major shareholder Sangsangin Investment & Securi sold 433,332 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $8.71, for a total transaction of $3,774,321.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 52.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on XCUR shares. Wall Street Zen upgraded shares of Exicure to a “hold” rating in a research note on Saturday, January 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Exicure in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Exicure Trading Up 0.8%

Shares of XCUR stock opened at $3.74 on Monday. Exicure has a 12 month low of $3.10 and a 12 month high of $15.91. The stock has a market cap of $23.82 million, a P/E ratio of -1.01 and a beta of 4.13. The company has a 50 day simple moving average of $4.98 and a two-hundred day simple moving average of $4.86.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.